The topic is short and compact
In adult acne, skin compatibility is the key performance feature because the skin reacts more sensitively and medical acne therapies put additional strain on the skin barrier.
Studies describe fewer ceramides in the stratum corneum and less linoleic acid in skin surface lipids in cases of acne; this supports the concept, but does not prove product efficacy.
Oils rich in linoleic acid and ceramides require antioxidants, precise phase management, and low-oxygen packaging to ensure the formulation remains stable.
Claims such as "treats acne" make a product resemble a medicinal product; "non-comedogenic" and "for blemish-prone skin" require evidence on the finished product.
Salicylic acid is limited to 2.0 percent in facial care; according to the 2025 SCCS opinion, a new formulation should not be planned at the maximum level.
So läuft die Entwicklung bei Labtree
1
Konzeptionierung
2
Bemusterung – Standardmuster in 24 h
3
Individualisierung
4
Prototyping
5
Produktion
White Label 2–3 Monate · Private Label 3–6 Monate · Produktion ab 1.000 Stück
Why is drying skincare not suitable for adult blemish-prone skin?
Because the skin of adult sufferers often reacts more sensitively and many classic acne active ingredients put additional strain on the barrier. A review by Branisteanu et al. (Experimental and Therapeutic Medicine, 2022) defines acne in women over 25 years of age as a distinct form of adult acne and cites a prevalence between 12 and 54 percent. The authors describe increased skin sensitivity with a higher tendency to irritation in this group; retinoids must be adapted to the more irritation-prone skin of older patients, and benzoyl peroxide over 5 percent is not recommended for this group.
Barrier stress caused by therapy is measurable. In the review by Thiboutot and Del Rosso on the epidermal barrier in acne, benzoyl peroxide 10 percent led to a 1.8-fold higher transepidermal water loss (TEWL). Retinoids frequently trigger retinoid dermatitis with redness and flaking in the first two weeks. In a study cited therein involving women between 35 and 55 years of age, a moisturizer applied two weeks before and during tretinoin treatment prevented the increase in TEWL.
What this means for the product concept
The target group consists of adults who are often undergoing medical treatment concurrently; cosmetic care complements this treatment, it does not replace it.
skin compatibility is the central performance feature, not the strength of the active ingredient.
Benzoyl peroxide and tretinoin from the cited studies are active ingredients of medical acne treatment: tretinoin is listed in Annex II of Regulation (EC) No 1223/2009 as amended among the prohibited substances; benzoyl peroxide is only permitted in artificial fingernail systems according to Annex III.
What role do skin lipids play in blemish-prone skin?
The literature describes an altered lipid composition of the skin in acne, and this is precisely where a lipid-based formulation comes in. Thiboutot and Del Rosso summarize a study involving 36 male patients between the ages of 14 and 26 with mild to moderate acne: higher sebum secretion, higher TEWL, lower hydration of the stratum corneum, and less free sphingosine and total ceramides than in the control group. Water loss and hydration were more severely altered in moderate acne than in mild acne. The data therefore originate predominantly from young men; their applicability to adult acne in women is limited.
A second finding concerns linoleic acid. According to the review paper Lipid Mediators in Acne by Ottaviani, Camera, and Picardo, the proportion of linoleic acid in the skin surface lipids of affected individuals is reduced, and the proportion of acylceramides containing linoleic acid is lower. The authors suspect that this deficiency contributes to follicular hyperkeratosis and comedone formation. Thiboutot and Del Rosso cite dilution of linoleic acid due to increased sebum flow as a possible explanation.
For product claims, the limitation of these findings is important: they concern mechanisms and observations in patient groups, not evidence of efficacy for a specific cream. A raw material with a high linoleic acid content does not prove the efficacy of the finished product. The formulation requires its own data if it intends to claim more than care and moisturization.
How is a lipid-based formulation for blemish-prone skin structured?
It combines a barrier-oriented lipid system with a light, minimally occlusive texture and a moderate active ingredient. The difficulty lies in the fact that precisely the lipids intended to support the barrier influence texture, comedogenicity, and shelf life. The following overview compares the formulation decisions:
Decision | Drying approach | Lipid-based approach | Check point |
|---|---|---|---|
Lipid system | Minimal, often oil-free | Ceramides, cholesterol, fatty acids, linoleic-acid-rich oils | Comedogenicity and oxidation in the finished product |
Texture | Gel, alcoholic solution | Light O/W emulsion or gel-cream | Viscosity and phase stability over storage |
active ingredient | High dosage, drying | Low dosage, tolerance-guided | Annex III limits and user test |
Emulsifier | Secondary | Barrier-mimicking, minimal surfactant content | skin compatibility on pre-damaged skin |
Claim | Effect against pimples | Care and appearance of blemished skin | Evidence according to Regulation (EU) No 655/2013 |
Typical formulation problems
Oxidation: Oils with a high proportion of polyunsaturated fatty acids such as linoleic acid oxidize more easily than saturated lipids. Antioxidants, nitrogen blanketing during manufacturing, and low-oxygen packaging prolong stability.
Ceramides: Ceramides are poorly soluble and crystallize if the phase process is incorrect. The temperature profile and incorporation must be defined in the laboratory and transferred to production scale.
Occlusivity: Heavy waxes and butters improve the barrier function, but increase the risk that the texture is perceived as too rich on blemished skin.
Which active ingredients are possible in cosmetic skincare for blemish-prone skin?
Active ingredients that are approved in the EU for cosmetic products and comply with the limits set out in the annexes to Regulation (EC) No 1223/2009 can be used cosmetically. Salicylic acid, niacinamide, and zinc compounds are frequently used. For dosage in adult acne, the same logic applies as with the lipid system: skin compatibility before strength.
Salicylic acid is a restricted substance. According to Annex III, entry 98 of Regulation (EC) No 1223/2009 as amended, the limits for purposes other than preservation are 3.0 percent in rinse-off hair products, 2.0 percent in other products, and 0.5 percent in body lotions, eye shadows, mascaras, eyeliners, lipsticks, and roll-on deodorants; products for children under 3 years of age are excluded. Facial care therefore falls under the 2.0 percent limit. In its opinion SCCS/1675/25 on salicylic acid in April 2025, the Scientific Committee on Consumer Safety concluded that these concentrations are not safe for children aged 3 to 10 years under aggregated exposure, and described salicylic acid as eye-irritating. In the consolidated version of May 18, 2026, the values remain unchanged; whether an amendment to the Annex will follow remains open. A new formulation should therefore not be planned at the maximum limit.
How salicylic acid can be formulated stably is described in the article Having BHA serum manufactured. In lipid-based care, it tends to appear as a secondary active ingredient in low doses, because it usually requires an acidic pH value of the formulation, which can reduce skin compatibility on compromised skin.
Where is the line between cosmetics and pharmaceuticals?
The boundary arises from intended purpose and presentation. According to Art. 2(1)(a) of Regulation (EC) No 1223/2009, cosmetic products are intended exclusively or mainly to clean the skin, perfume it, change its appearance, protect it, keep it in good condition, or correct body odors. A product claimed to cure acne or treat inflammation falls outside this scope. The European Commission notes on its page on borderline products that classification is determined on a case-by-case basis and refers to its manual on the scope of the regulation.
For advertising claims, Art. 20 of Regulation (EC) No 1223/2009 applies together with the common criteria of Regulation (EU) No 655/2013: legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making. Claims such as “non-comedogenic,” “for blemish-prone skin,” or “strengthens the skin barrier” must be supported by tests on the finished product or by reliable data.
Comparison of claims
Cosmetically acceptable, if substantiated: “cares for blemish-prone skin,” “supports the skin barrier,” “reduces the appearance of blemishes.”
Bordering on medicinal: “treats acne,” “anti-inflammatory against pimples,” “acts against hormonal acne.”
The rules are explained in detail in the article Cosmetic advertising claims in the EU.
What testing does care need prior to launch?
In addition to the safety assessment in accordance with Article 10 of Regulation (EC) No 1223/2009, four testing areas are decisive for lipid-based care for blemish-prone skin. They should run parallel to formulation development, not afterwards.
Stability in the final container: Storage at elevated and varying temperatures, with a view to phase separation, viscosity drift, odor, and color. With oils rich in linoleic acid, oxidation is often first noticeable by odor.
Preservative challenge test according to ISO 11930: Water-based emulsions need an effective preservative system; the test evaluates it with assessments over 28 days.
skin compatibility: For products intended for sensitive, pre-treated skin, an in-use test under dermatological supervision is recommended to substantiate skin compatibility claims.
Comedogenicity: If "non-comedogenic" is claimed, substantiation on the finished product is required; data on individual raw materials is not sufficient.
The packaging material is part of the testing. A jar exposes the product to oxygen and germs every time it is opened, whereas airless dispensers and tubes better protect oxidation-sensitive lipids. The complete scope of testing is described in Stability and safety testing for cosmetics.
Labtree is a B2B cosmetics developer and cosmetics manufacturer with its own laboratory, covering formulation development, in-house laboratory work, sampling, manufacturability testing, and cosmetics production. For lipid-based care, this means: the lipid system, active ingredient dosage, and phase control are coordinated in the laboratory for skin compatibility, texture, and stability, and manufacturability is already tested during development.
Samples of pre-qualified formulations are usually shipped from the sample warehouse within 24 hours. Under white label, Labtree adapts a tested proprietary formulation to the brand, ready for delivery with standard packaging usually in 2 to 3 months; the formulation remains with Labtree. Under private label, a new development is created according to the brand's requirements, typically taking 3 to 6 months to reach market readiness. The minimum order quantity is usually 1,500 units per product, depending on the product type, fill size, and packaging.
The target audience overlaps with concepts for skin during hormonal transitional phases, which the article Skincare in Perimenopause addresses.
Quellen
More useful links
FAQ
Can cosmetics be advertised as "anti-acne"?
No, a claim such as "treats acne" describes a therapeutic effect and shifts the product into the medicinal category. Claims regarding the care and appearance of blemish-prone skin are permitted for cosmetics, provided they are substantiated in accordance with Regulation (EU) No. 655/2013. The classification of borderline products is determined on a case-by-case basis.
How much salicylic acid is permitted in cosmetics?
According to Annex III of Regulation (EC) No 1223/2009, limits are 2.0 percent for most products including facial care, 3.0 percent for rinse-off hair products, and 0.5 percent for items such as body lotions and lipsticks. In 2025, the SCCS evaluated these levels as not safe for children aged 3 to 10 years when multiple products are used concurrently. For new formulations, it is therefore recommended to maintain a dosage well below the maximum limit.
Is "non-comedogenic" a permissible advertising claim?
Yes, if it has been proven for the finished product. Data on individual oils or emulsifiers is not enough, as concentration, combination, and texture alter the result. The proof must be included in the product information file.
Which oils are suitable for caring for blemish-prone skin?
Oils with a high linoleic acid content are frequently chosen because studies show reduced linoleic acid levels in the surface lipids of acne-prone skin. These oils oxidize more easily, which is why they require antioxidants, a suitable manufacturing process, and low-oxygen packaging. Whether the blend is well-tolerated on blemish-prone skin can only be confirmed by testing the finished product.
Can a product for blemish-prone skin also be makeup?
Yes, for example as a skin tint or concealer for blemish-prone skin. The same requirements regarding skin compatibility, comedogenicity, and advertising claims then apply, and coverage, pigment dispersion, and longevity must also be right. Background information on coverage is provided in the magazine article Concealer produzieren lassen.
How long does it take to develop skincare for blemish-prone skin?
At Labtree, a customized white-label product with standard packaging is generally ready for delivery in 2 to 3 months, while a newly developed private-label product usually takes 3 to 6 months to reach market maturity. The timeline is primarily determined by stability testing, skin compatibility tests, and the alignment of claims. The magazine article on realistic timelines in cosmetics development describes which factors can extend timelines.





